SCHEMBL2193784

SCHEMBL2193784

Cn1nc(C2CCCCC2)[nH]c1=[Pt].Fc1ccc(CN(I)I)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.36
MAPK13 O15264 1/20 0.36
RAF1 P04049 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
GCGR P47871 1/20 0.32
ADORA1 P30542 1/20 0.32
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CHRM1 P11229 4/20 0.31
HRH1 P35367 4/20 0.31
CYP2D6 P10635 3/20 0.31
TSHR P16473 2/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HSD17B10 Q99714 1/20 0.31
KCNH2 Q12809 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192454 0.90 ADORA1 (0.38) ADORA1SLC6A2SLC6A4KDM4EALDH1A1
SCHEMBL2192374 0.89 MEN1 (0.31) MEN1KMT2AADORA2AADORA2B
SCHEMBL2193146 0.89 LSS (0.38) GCGRADORA1SLC6A2SLC6A4SLC6A3
SCHEMBL2198292 0.89 ADORA3 (0.38) ADORA1KDM4EALDH1A1MEN1LMNA
SCHEMBL2195657 0.88 ADORA1 (0.41) ADORA1SLC6A2SLC6A4KDM4EALDH1A1
SCHEMBL2195966 0.76 ADORA2A (0.33) ADORA1SMN1; SMN2LMNAADORA2AADORA2B
SCHEMBL2192944 0.76 ADORA2A (0.33) ADORA1SMN1; SMN2LMNAADORA2AADORA2B
SCHEMBL2268158 0.76 ADORA2A (0.33) ADORA1SMN1; SMN2LMNAADORA2AADORA2B
SCHEMBL2196243 0.76 ADORA2A (0.33) ADORA1SMN1; SMN2LMNAADORA2AADORA2B
SCHEMBL2193102 0.74 ALOX5 (0.40) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPK14 3763/4885MAPK13 3538/4885RAF1 1308/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPK14 3763/4885MAPK13 3538/4885RAF1 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.